Trial Profile

PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

Most Recent Events

16 Apr 2023 Status changed from recruiting to discontinued. Due to lack of results, study has been early terminated.
20 Jan 2018 Results of pool data from two parallel phases II trials (NCT02677038 and NCT02511223) assessing the efficacy of olaparib in advanced PDAC with BRCAness, were presented at the 2018 Gastrointestinal Cancers Symposium.
27 Sep 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com